RxDoctor Payments Data

Allison Hernquist

Adult Health · Aurora, CONPI 1003571241

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,966 of the $2,984 with a category attached, or 65.9%. 18 manufacturers reported payments, led by Livanova USA, Inc. at 50.4% of the total. Reporting peaked in 2022 at $1,771 and has fallen 61.0% since, to $691 in 2025.

$2,984in general payments, 2019–2025

Across 61 payments — averaging $48.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$301
  • UCB, Inc.$216
  • Globus Medical$190
  • Jazz Pharmaceuticals Inc.$114
  • AbbVie$107
  • plus $553 from 12 others

What the payments were for

  • Travel & lodging$1,01834%
  • Food & beverage$1,96666%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,984 in reported general payments places this provider in the 85th percentile of 430 adult health providers in Colorado.

See all adult health providers in Colorado

Medicare billing

Part B allowed, 2024
$21,697
Medicare patients
132
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)12$88,468
BriviactBrivaracetam46$78,959
XcopriCenobamate49$65,774
LamictalLamotrigine35$57,089
TopamaxTopiramate11$23,348
BelbucaBuprenorphine Hcl30$20,994
Lacosamide78$16,441
Lamotrigine OdtLamotrigine18$15,839
NayzilamMidazolam16$13,267
Carbamazepine ErCarbamazepine19$7,550
Xtampza ErOxycodone Myristate13$7,353
Levetiracetam81$5,161
Buprenorphine13$4,263
Clobazam38$2,989
Lamotrigine100$2,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$216$92,22662 claims
SK Life Science, Inc.Xcopri$90$65,77449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 430 adult health providers in Colorado.

Other adult health in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →